Droplex ESR1 Mutation Test
Detection of 16 defined mutations within the ligand-binding domain of the ESR1-gene
Features
Breast cancer (BC) is the most common type of cancer and the second leading cause of death in women. Approximately 71 % of all breast cancer patients have a tumor of the ER+ and HER2 type. Up to 40 % of ER+/HER2 positive patients show ESR1 mutations in exons 5, 7, and 8, which are considered as the cause of resistance to standard endocrine therapy. Innovations in endocrine therapy are already showing significant treatment success in cases with activating ESR1 mutations.
The CE-IVD certified Droplex ESR1 Mutation Test detects 16 defined mutations within the ESR1 gene using Digital DropletTM technology.
Biomarkers
Exon 5: E380Q
Exon 7: S463P
Exon 8: V534E, L536P/R/Q/H, Y537S/C/N/H/D, D538G
Product specifications
- Cat No.
- CD009
- Cancer type
- Breast cancer
- Regulatory status
- CE-IVD
- Compatible sample type
- DNA from FFPE tissue, for RUO application: cfDNA from Plasma
- Mutation variants
- 16
- Kit size/ reactions
- 24 samples/kit (2 well-reactions/sample)
- Platform
- Digital DropletTM PCR
Resources
Ordering Information
Droplex ESR1 Mutation Test
Size: 24 samples/kit (2 well-reactions/sample)
Cat.No.: CD009
Status: CE-IVD
Product Request
MODAPLEX
Bench-top system for molecular multi-marker testing
